Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells

References

• US Food and Drug Administration. KYMRIAH (tisagenlecleucel); 2017 Aug 30 and 2018 May 1. https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/approvedproducts/ucm573706.htm.
   Google Scholar
• US Food and Drug Administration. YESCARTA (axicabtagene ciloleucel); 2017 Oct 18. https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm.
   Google Scholar
• First-ever CAR T-cell therapy approved in U.S. Cancer Discov. 2017 [cited 2018 Jul 28]accessed;7:OF1. http://cancerdiscovery.aacrjournals.org/content/7/10/OF1.
   Web of Science ®Google Scholar
• Salmikangas P, Kinsella N, Chamberlain P. Chimeric antigen receptor T-cells (CAR T-cells) for cancer immunotherapy – moving target for industry? Pharm Res. 2018;35:152. doi:10.1007/s11095-018-2436-z.
   PubMed Web of Science ®Google Scholar
• Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018;23:1175–82. doi:10.1016/j.drudis.2018.02.012.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–95. doi:10.1182/blood-2014-05-552729.
   PubMed Web of Science ®Google Scholar
• June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–65. doi:10.1126/science.aar6711.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51. doi:10.1038/mt.2010.24.
   PubMed Web of Science ®Google Scholar
• Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol. 2013;31:999–1008. doi:10.1038/nbt.2725.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber D, Schneck J, Gabrilovich D. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828–35. doi:10.1038/nm1609.
   PubMed Web of Science ®Google Scholar
• Jackson HJ, Brentjens RJ. Overcoming antigen escape with CAR T-cell therapy. Cancer Discov. 2015;5:1238–40. doi:10.1158/2159-8290.CD-15-1275.
   PubMed Web of Science ®Google Scholar
• Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, Gustafsson K, Anderson J. Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther. 2017;25:1234–47. doi:10.1016/j.ymthe.2017.03.002.
   PubMed Web of Science ®Google Scholar
• Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, Clackson T. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97:1249–57.
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:913–24. doi:10.1016/j.bbmt.2007.04.005.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22:1875–84. doi:10.1158/1078-0432.CCR-15-1433.
   PubMed Web of Science ®Google Scholar
• Chu F, Cao J, Neelalpu SS. Versatile CAR T-cells for cancer immunotherapy. Contemp Oncol (Pozn). 2018;22:73–80. doi:10.5114/wo.2018.73892.
   PubMedGoogle Scholar
• Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019 Jan;120(1):26–37. doi:10.1038/s41416-018-0325-1.
   Web of Science ®Google Scholar
• Zah E, Lin MY, Silva-Benedict A, Jensen MC, Chen YY. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498–508. doi:10.1158/2326-6066.CIR-15-0231.
   PubMed Web of Science ®Google Scholar
• Martyniszyn A, Krahl AC, Andre MC, Hombach AA, Abken H. CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies. Hum Gene Ther. 2017;28:1147–57. doi:10.1089/hum.2017.126.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–28. doi:10.1038/nm.4441.
   PubMed Web of Science ®Google Scholar
• Hammill JA, VanSeggelen H, Helsen CW, Denisova GF, Evelegh C, Tantalo DG, Bassett JD, Bramson JL. Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. J Immunother Cancer. 2015;3:55. doi:10.1186/s40425-015-0099-4.
   PubMed Web of Science ®Google Scholar
• De Munter S, Ingels J, Goetgeluk G, Bonte S, Pille M, Weening K, Kerre T, Abken H, Vandekerckhove B. Nanobody based dual specific CARs. Int J Mol Sci. 2018;19:403. doi:10.3390/ijms19020403.
   Web of Science ®Google Scholar
• Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, Yu J, Scholler N, Powell DJ. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72:1844–52. doi:10.1158/0008-5472.CAN-11-3890.
   PubMed Web of Science ®Google Scholar
• Albert S, Arndt C, Koristka S, Berndt N, Bergmann R, Feldmann A, Schmitz M, Pietzsch J, Steinbach J, Bachmann M. From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo. Oncotarget. 2018;9:25597–616. doi:10.18632/oncotarget.25390.
   PubMedGoogle Scholar
• Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A. 2016;113:E450–8. doi:10.1073/pnas.1524193113.
   PubMed Web of Science ®Google Scholar
• Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, Mazagova M, Choi S-H, Yun HY, Xiao H, et al. Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angew Chem Int Ed Engl. 2016;55:7520–24. doi:10.1002/anie.201601902.
   PubMed Web of Science ®Google Scholar
• Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, Schulman A, Du J, Wang F, Singer O, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A. 2016;113:E459–68. doi:10.1073/pnas.1524155113.
   PubMed Web of Science ®Google Scholar
• Hermanson GT. Bioconjugate Techniques. Copyright © 2013, 1996, 2008. Elsevier Inc. All rights reserved; 2013.
   Google Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9:86–120. doi:10.1007/s13238-017-0457-8.
   PubMed Web of Science ®Google Scholar
• Townsend MH, Shrestha G, Robison RA, O’Neill KL. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 2018;37:163.
   PubMed Web of Science ®Google Scholar
• Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, Wang D, Woods A, Sherwood L, Caballero D, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015;137:2832–35. doi:10.1021/jacs.5b00106.
   PubMed Web of Science ®Google Scholar
• Chu W, Zhou Y, Tang Q, Wang M, Ji Y, Yan J, Yin D, Zhang S, Lu H, Shen J. Bi-specific ligand-controlled chimeric antigen receptor T-cell therapy for non-small cell lung cancer. Biosci Trends. 2018;12:298–308. doi:10.5582/bst.2018.01048.
   PubMed Web of Science ®Google Scholar
• Krall N, Scheuermann J, Neri D. Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed Engl. 2013;52:1384–402. doi:10.1002/anie.201204631.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer. 2011;74:188–96. doi:10.1016/j.lungcan.2011.04.009.
   PubMed Web of Science ®Google Scholar
• Lee YG, Marks I, Srinivasarao M, Kanduluru AK, Mahalingam SM, Liu X, Chu H, Low PS. Use of a single CAR T cell and several bispecific adapters facilitates eradication of multiple antigenically different solid tumors. Cancer Res. 2019;79:387–96. doi:10.1158/0008-5472.CAN-18-1834.
   PubMed Web of Science ®Google Scholar
• Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 2008;49:788–95. doi:10.2967/jnumed.107.048538.
   PubMed Web of Science ®Google Scholar
• Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A, Gärtner S, et al. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology. 2017;6:e1287246. doi:10.1080/2162402X.2017.1287246.
   PubMed Web of Science ®Google Scholar
• Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, Wiefel K, Stamova S, Schmitz M, Ehninger G, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013;42:105–16. doi:10.1016/j.jaut.2013.01.002.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6:e458. doi:10.1038/bcj.2016.61.
   PubMed Web of Science ®Google Scholar
• Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, Pietzsch J, Novo C, Videira P, Bachmann M. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018;8:81. doi:10.1038/s41408-018-0113-4.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, Aliperta R, Hetzenecker M, Ludwig F, Albert S, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”. Oncotarget. 2017;8:31368–85. doi:10.18632/oncotarget.15572.
   PubMedGoogle Scholar
• Ehninger A, Kramer M, Rollig C, Thiede C, Bornhauser M, von Bonin M, Wermke M, Feldmann A, Bachmann M, Ehninger G, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218. doi:10.1038/bcj.2014.39.
   PubMed Web of Science ®Google Scholar
• Herrington-Symes AP, Farys M, Khalili H, Brocchini S. Antibody fragments: prolonging circulation half-life special issue-antibody research. Adv Biosci Biotechnol. 2013;04:689–98. doi:10.4236/abb.2013.45090.
   Google Scholar
• Viaud S, Ma JSY, Hardy IR, Hampton EN, Benish B, Sherwood L, Nunez V, Ackerman CJ, Khialeeva E, Weglarz M, et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc Natl Acad Sci U S A. 2018;115:E10898–E906. doi:10.1073/pnas.1810060115.
   PubMed Web of Science ®Google Scholar
• Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720–24.
   PubMed Web of Science ®Google Scholar
• Kong S, Sengupta S, Tyler B, Bais AJ, Ma Q, Doucette S, Zhou J, Sahin A, Carter BS, Brem H, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res. 2012;18:5949–60. doi:10.1158/1078-0432.CCR-12-0319.
   PubMed Web of Science ®Google Scholar
• Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P. Adnectin-based design of chimeric antigen receptor for T cell engineering. Mol Ther. 2017;25:2466–76. doi:10.1016/j.ymthe.2017.07.009.
   PubMed Web of Science ®Google Scholar
• Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64:9160–66. doi:10.1158/0008-5472.CAN-04-0454.
   PubMed Web of Science ®Google Scholar
• Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D’Apuzzo M, Barish ME, Forman SJ, Jensen MC. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012;18:2199–209. doi:10.1158/1078-0432.CCR-11-1669.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005;106:1544–51. doi:10.1182/blood-2004-11-4365.
   PubMed Web of Science ®Google Scholar
• Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, Dotti G, Wu M-F, Liu H, Kenney S, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood. 2011;117:4304–14. doi:10.1182/blood-2010-04-278218.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21:4062–72. doi:10.1158/1078-0432.CCR-15-0428.
   PubMed Web of Science ®Google Scholar
• Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, Chng WJ, Campana D. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74:93–103. doi:10.1158/0008-5472.CAN-13-1365.
   PubMed Web of Science ®Google Scholar
• Clémenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, Vié H. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107:4669–77. doi:10.1182/blood-2005-09-3775.
   PubMed Web of Science ®Google Scholar
• Ochi F, Fujiwara H, Tanimoto K, Asai H, Miyazaki Y, Okamoto S, Mineno J, Kuzushima K, Shiku H, Barrett J, et al. Gene-modified human alpha/beta-T cells expressing a chimeric CD16-CD3zeta receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy. Cancer Immunol Res. 2014;2:249–62. doi:10.1158/2326-6066.CIR-13-0099-T.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, et al. Development of engineered T cells expressing a chimeric CD16-CD3zeta receptor to improve the clinical efficacy of mogamulizumab therapy against adult T-cell leukemia. Clin Cancer Res. 2016;22:4405–16. doi:10.1158/1078-0432.CCR-15-2714.
   PubMed Web of Science ®Google Scholar
• Rataj F, Jacobi SJ, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha BL, van Puijenbroek E, Heise C, Duewell P, et al. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. Br J Cancer. 2019 Jan;120(1):79–87. doi:10.1038/s41416-018-0341-1.
   PubMed Web of Science ®Google Scholar
• Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7:e1368604. doi:10.1080/2162402X.2017.1368604.
   PubMed Web of Science ®Google Scholar
• Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173:1426–1438. doi:10.1016/j.cell.2018.03.038.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity. 2006;24:19–28. doi:10.1016/j.immuni.2005.11.010.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317–27. doi:10.1038/nri2744.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Marabelle A, Cho HJ, Osman K, Goldstein M, Levy R, Brody J. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4:511–27. doi:10.2217/imt.12.38.
   PubMed Web of Science ®Google Scholar
• D’Aloia MM, Caratelli S, Palumbo C, Battella S, Arriga R, Lauro D, Palmieri G, Sconocchia G, Alimandi M. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. Cytotherapy. 2016;18:278–90. doi:10.1016/j.jcyt.2015.10.014.
   PubMed Web of Science ®Google Scholar
• Michaels J. Unum Therapeutics Announces Presentation of Initial Clinical Data from the ATTCK-20-2 Trial and Pre-Clinical Data on its Antibody-Coupled T Cell Receptor (ACTR) Platform at the Upcoming 59th American Society of Hematology (ASH) Annual Meeting. BUSINESS WIRE, November 01, 2017 Report about oral presentation from Presentation Title: ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-cell Lymphoma, in Combination with Rituximab Authors (affiliation): L. Akard (IBMT), S. Jaglowski (OSU), S. Devine (OSU), M. McKinney (Duke), M. Vasconcelles, H. Huet, S. Ettenberg, A. Ranger, J. Abramson (MGH). https://www.businesswire.com/news/home/20171101005626/en/Unum-Therapeutics-Announces-Presentation-Initial-Clinical-Data.
   Google Scholar
• Cheema T, Hickman T, O’Callaghan K, Westendorf L, Manlove L, Gardai S, Nelson A, Boomer R, McGinness K, Schultes B, et al. Abstract 4605: efficient targeting of BCMA-positive multiple myeloma cells by antibody-coupled T-cell receptor (ACTR) engineered autologous T cells in combination with an anti-BCMA antibody. Cancer Res. 2017;77:4605. doi:10.1158/1538-7445.AM2017-4605.
   Web of Science ®Google Scholar
• Inc. UT. Unum Therapeutics Inc.; 2018. https://www.unumrx.com/pipeline.
   Google Scholar
• Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115:4393–402. doi:10.1182/blood-2009-06-225979.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–73. doi:10.1074/jbc.M210665200.
   PubMed Web of Science ®Google Scholar
• Lim KH, Huang H, Pralle A, Park S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol Bioeng. 2013;110:57–67. doi:10.1002/bit.24605.
   PubMed Web of Science ®Google Scholar
• Qureshi MH, Yeung JC, Wu SC, Wong SL. Development and characterization of a series of soluble tetrameric and monomeric streptavidin muteins with differential biotin binding affinities. J Biol Chem. 2001;276:46422–28. doi:10.1074/jbc.M107398200.
   PubMed Web of Science ®Google Scholar
• Fonseca MHG, Furtado GP, Bezerra MRL, Pontes LQ, Fernandes CFC. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: an interaction-function review. Int J Biol Macromol. 2018;119:306–11. doi:10.1016/j.ijbiomac.2018.07.141.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z,  Robak T, Maddocks K, Buske C, Ambarkhane S, et al. Single-agent MOR208 in relapsed or refractory (R-R) Non-Hodgkin’s Lymphoma (NHL): results from Diffuse Large B-Cell Lymphoma (DLBCL) and indolent NHL subgroups of a Phase IIa Study. Blood. 2016;128:623. doi:10.1182/blood-2016-06-724161.
   Google Scholar
• Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21. doi:10.3389/fphar.2015.00021.
   PubMed Web of Science ®Google Scholar
• MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, Broady R, Levings MK. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413–24. doi:10.1172/JCI82771.
   PubMed Web of Science ®Google Scholar
• Deuse T, Hu X, Gravina A, Wang D, Tediashvili G, De C, Thayer WO, Wahl A, Garcia JV, Reichenspurner H, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37:252–58. doi:10.1038/s41587-019-0016-3.
   PubMed Web of Science ®Google Scholar
• Cartellieri M, Koristka S, Arndt C, Feldmann A, Stamova S, von Bonin M, Töpfer K, Krüger T, Geib M, Michalk I, et al. A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells. PLoS One. 2014;9:e93745. doi:10.1371/journal.pone.0093745.
   PubMed Web of Science ®Google Scholar
• Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, Davila E. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18:6436–45. doi:10.1158/1078-0432.CCR-12-1449.
   PubMed Web of Science ®Google Scholar
• van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJG, van der Zee AGJ, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med. 2011;17:1315–19. doi:10.1038/nm.2472.
   PubMed Web of Science ®Google Scholar